Latest Endo Pharmaceuticals Stories
Brings Extensive Leadership And Operations Experience in Healthcare Industry MALVERN, Pa., Feb. 25, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Rajiv De Silva, a pharmaceutical executive who had been President of Valeant Pharmaceuticals and a senior executive at Novartis, has been named Endo's President and Chief Executive Officer, effective March 18. Mr. De Silva, who will also join the Endo Board of Directors, succeeds David Holveck who is...
LONDON, February 25, 2013 /PRNewswire/ -- The drug manufacturing sector is always on the run. While some companies are getting new product approvals, others are being targeted for a takeover bid. Allergan Inc. (NYSE: AGN) is looking to perform better this year with new FDA approval for its breast implants. Endo Health Solutions Inc. (NASDAQ: ENDP), on the other hand, is on the verge of being acquired. Apart from this, the company's stock is also being lapped up by hedge...
CHADDS FORD, Pa., Dec. 19, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that U.S. District Judge Reggie B. Walton, of the U.S. District Court for the District of Columbia, dismissed the case of Endo's subsidiary, Endo Pharmaceuticals Inc., against the U.S. Food and Drug Administration (FDA). Endo Pharmaceuticals argued that FDA failed to meet its legal obligation to determine in a timely manner whether the original formulation of OPANA ER was...
CHADDS FORD, Pa., Dec. 12, 2012 /PRNewswire/ -- Dave Holveck To Retire By May 2013 Board Conducting Search For Next CEO Comments on 2012 and 2013 Full Year Financial Guidance Endo Health Solutions Inc. (Nasdaq: ENDP) announced today David P. Holveck, 67, President and Chief Executive Officer, will retire in 2013. He will continue to serve in his present positions until the earlier of his successor being in place or the May 2013 annual meeting of Endo shareholders. Holveck will...
CHADDS FORD, Pa., Nov. 13, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has supplemented its OPANA(®) ER Citizen Petition to include emerging safety data that demonstrate that the introduction in the first quarter of 2012 of the reformulated OPANA ER (oxymorphone HCl) designed to be crush-resistant, is reducing rates of abuse. Comparisons of abuse rates for OPANA ER, from the third quarter of 2011...
TEL AVIV, Israel, November 13, 2012 /PRNewswire/ -- The Trendlines Group today announced it has entered into an R&D agreement aimed at co-developing novel medical devices and technologies within the areas of pain and urology, a strategic focus of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP). The work will be conducted by Trendlines Labs, the technology development arm of The Trendlines Group. Trendlines Labs is co-located with the Misgav Venture Accelerator...
CHADDS FORD, Pa., Nov. 8, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that Julie McHugh, chief operating officer, will present a corporate overview at the 2012 Annual Credit Suisse Healthcare Conference on Thursday, Nov. 15, 2012, at 1:00 p.m. MST (3:00 p.m. ET). The conference will be held at the Arizona Biltmore in Phoenix. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/. Click...
CHADDS FORD, Pa., Nov. 7, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that Alan Levin, chief financial officer, will present a corporate overview at the Jefferies 2012 Global Healthcare Conference on Wednesday, Nov. 14, 2012, at 8:00 a.m. GMT (3:00 a.m. ET). The conference will be held at the Waldorf Hilton in London. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/. Click on...
-Bioniche and Endo discussing potential next steps for Urocidin(TM) clinical program- BELLEVILLE, ON, Nov. 5, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin(TM) in non-muscle-invasive bladder cancer is being discontinued. The trial, a randomized, active-controlled, open-label, multi-center study with a blinded endpoint...
MISSISSAUGA, ON, Oct. 31, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the third quarter ended September 30, 2012. Third Quarter and Recent Corporate Developments: -- The Company was informed by Galderma that it has received...
